Total Funding
88
74
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
47184
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders.
- Helen Barker: Chief Technology OfficerPast Role: Vicore Pharma, VP and Head of CMC
- Bernt Blink: Chief Medical OfficerPast Role: Vicore Pharma, Vice President of Clinical Development
About the Company
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU
and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
